HPK1-inhibitor(Ryvu)

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameHPK1-inhibitor(Ryvu)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase kinase 1 inhibitors
TargetsMitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A